Syndax Pharmaceuticals (SNDX) Total Liabilities (2015 - 2026)

Syndax Pharmaceuticals' Total Liabilities history runs 12 years deep, the most recent figure standing at $431.0 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 1.27% year-over-year to $431.0 million in Q1 2026; TTM through Mar 2026 was $431.0 million, a 1.27% increase from a year earlier, with the FY2025 full-year figure at $465.1 million, up 6.5% from the prior year.
• Total Liabilities retreated to $431.0 million in Q1 2026 per SNDX's latest filing, from $465.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $465.1 million in Q4 2025 and bottomed at $21.6 million in Q3 2022.
• The 5-year median for Total Liabilities is $51.1 million (2024), against an average of $181.4 million.
• Across the five-year window, Total Liabilities sank 48.98% in 2023 and soared 929.65% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $29.8 million in 2022, then soared by 97.01% to $58.7 million in 2023, then soared by 644.14% to $436.7 million in 2024, then increased by 6.5% to $465.1 million in 2025, then slipped by 7.32% to $431.0 million in 2026.
• Per Business Quant, the three latest SNDX Total Liabilities figures stand at $431.0 million (Q1 2026), $465.1 million (Q4 2025), and $436.4 million (Q3 2025).